ETANERCEPT FOR TREATMENT OF SUB-ACUTE PULM DYSFUNCTION AFTER ALLOGENEIC BMT

依那西普治疗同种异体 BMT 后亚急性肺功能障碍

• 批准号: 7603828
• 负责人: GREGORY A YANIK
• 金额: $ 0.57万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603828
• 关键词: Acute; Adverse effects; Allogeneic Bone Marrow Transplantation; Arts; Back; Bone Marrow Transplantation; Chronic; Clinical; Complication; Computer Retrieval of Information on Scientific Projects Database; Etanercept; Functional disorder; Funding; Grant; Immune system; Injury; Institution; Laboratories; Lung; Lymphoma; Modeling; Mus; Patients; Pharmaceutical Preparations; Proteins; Research; Research Personnel; Resources; Source; Techniques; Transplantation; Tumor Necrosis Factor-alpha; United States Food and Drug Administration; United States National Institutes of Health; base; human TNF protein; insight; leukemia; lung injury; novel; success

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Allogeneic bone marrow transplantation (BMT) is the only curative treatment for many patients with leukemia or lymphoma. Unfortunately, injury to the lung is common after allogeneic BMT and limits the success of this therapy. Lung injury occurs early and late after BMT and can be either infectious or non-infectious in origin. Non-infectious lung injury occurring months to years after transplant is particularly troublesome for our patients. Historically, medications that weaken the immune system have been the mainstay of therapy, but this approach is rarely successful and has considerable side effects. Using mouse BMT models, we have determined that a protein called TNF alfa contributes to lung injury in this context. Importantly, we have brought this exciting laboratory discovery back to our patients using an FDA approved drug (etanercept) that neutralizes the effects of TNFx, and found that this drug is safe and potentially effective in our patients with chronic lung injury. This proposal will, therefore, build upon prior laboratory clinical insights and will combine a novel research trial with state of the art laboratory techniques to: 1) determine whether etanercept is an effective treatment for our BMT patients, and 2) further our understanding of the biologic basis of this complication.'

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 异基因骨髓移植（BMT）是许多白血病或淋巴瘤患者的唯一治愈性治疗方法。 不幸的是，肺损伤是常见的同种异体骨髓移植后，限制了这种治疗的成功。 肺损伤发生在骨髓移植后的早期和晚期，可以是感染性的或非感染性的。 移植后数月至数年发生的非感染性肺损伤对我们的患者来说特别麻烦。 从历史上看，削弱免疫系统的药物一直是治疗的支柱，但这种方法很少成功，而且有相当大的副作用。 使用小鼠BMT模型，我们已经确定了一种称为TNF α的蛋白质在这种情况下有助于肺损伤。 重要的是，我们使用FDA批准的药物（依那西普）将这一令人兴奋的实验室发现带回给我们的患者，该药物可中和TNFx的作用，并发现该药物对我们的慢性肺损伤患者是安全的，并且可能有效。 因此，该提案将建立在先前的实验室临床见解的基础上，并将联合收割机与最先进的实验室技术相结合，以：1）确定依那西普是否是我们BMT患者的有效治疗方法，2）进一步了解这种并发症的生物学基础。'